S. Cardin et al., DIFFERENT EFFECTS OF INDOMETHACIN AND NABUMETONE ON PROSTAGLANDIN-MEDIATED GASTRIC RESPONSES TO CENTRAL VAGAL ACTIVATION IN RATS, The Journal of pharmacology and experimental therapeutics, 275(2), 1995, pp. 667-673
Intracisternal injection of a stable thyrotropin-releasing hormone (TR
H) analog increases gastric prostaglandins release and mucosal resista
nce to injury through central vagal pathways. The effects of two nonst
eroidal anti-inflammatory drugs, indomethacin (INDO) and nabumetone on
intracisternal injection of various doses of TRH-induced gastric acid
secretion and changes in mucosal resistance were investigated in uret
hane-anesthetized rats. Doses of INDO (5 mg/kg) and nabumetone (13.75
mg/kg) producing similar acute anti-inflammatory response in the carra
geenin-induced paw edema were injected i.p. in all studies. INDO poten
tiated the acid secretion induced by intracisternal injection of TRH a
t 25, 50 and 200 ng by 5.1-, 1.9- and 1.4-fold, respectively, whereas
nabumetone did not modify the secretory response to TRH. Moderate eros
ions were observed in 100% of rats treated with the combination of IND
O and TRH (200 ng) whereas no erosions were observed when TRH or INDO
were given alone or TRH in combination with nabumetone. TRH at 7 ng re
duced mucosal damage induced by intragastric administration of ethanol
(60%, 1 ml/kg) by 63%. The mucosal protective action of TRH was aboli
shed by INDO but not altered by nabumetone pretreatment. These data in
dicate that at comparable anti-inflammatory doses, nabumetone, unlike
INDO, neither blocks the protection against ethanol injury induced by
low doses of TRH injected intracisternally nor potentiates the gastric
acid secretion or lesions induced by higher dose of TRH. We speculate
that these differences reflect reduced inhibition of gastric prostagl
andins by nabumetone.